PUMA BIOTECHNOLOGY, INC. (PBYI)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 52,436 | 46,007 | 80,542 | 47,083 |
| Selling, general and administrative | 18,047 | 17,604 | 16,819 | 24,972 |
| Research and development | 15,452 | 13,863 | 12,547 | 13,632 |
| Cost of sales | 12,301 | 10,556 | 29,097 | 10,658 |
| Total operating costs and expenses | 45,800 | 42,023 | 58,463 | 49,262 |
| Income (loss) from operations | 6,636 | 3,984 | 22,079 | -2,179 |
| Other income | 410 | 359 | 347 | 156 |
| Interest income | 956 | 1,101 | 1,282 | 1,244 |
| Interest expense | 1,837 | 2,177 | 3,100 | 3,372 |
| Total other expenses, net | -471 | -717 | -1,471 | -1,972 |
| Net income (loss) before income taxes | 6,165 | 3,267 | 20,608 | -4,151 |
| Income tax expense | 310 | 293 | - | - |
| Us-gaap_incometaxexpensebenefit | - | - | 291 | 378 |
| Net income (loss) | 5,855 | 2,974 | 20,317 | -4,529 |
| Basic (in dollars per share) | 0.12 | 0.06 | 0.41 | -0.09 |
| Diluted (in dollars per share) | 0.12 | 0.06 | 0.41 | -0.09 |
| Weighted average common stock outstanding for basic net income (loss) per share (in shares) | 49,700,217 | 49,595,697 | 49,008,464 | 48,292,414 |
| Weighted-average shares of common stock outstandingdiluted (in shares) | 50,144,704 | 49,906,341 | 49,173,361 | 48,292,414 |